BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 32473656)

  • 1. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
    Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
    Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
    Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
    Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
    Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
    J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
    Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
    J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
    Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
    Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
    Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N
    J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
    Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD
    Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASCL1 represses a SOX9
    Olsen RR; Ireland AS; Kastner DW; Groves SM; Spainhower KB; Pozo K; Kelenis DP; Whitney CP; Guthrie MR; Wait SJ; Soltero D; Witt BL; Quaranta V; Johnson JE; Oliver TG
    Genes Dev; 2021 Jun; 35(11-12):847-869. PubMed ID: 34016693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells.
    Wang XD; Hu R; Ding Q; Savage TK; Huffman KE; Williams N; Cobb MH; Minna JD; Johnson JE; Yu Y
    Nat Commun; 2019 Jul; 10(1):3201. PubMed ID: 31324758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.
    Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T
    Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Killing SCLC: insights into how to target a shapeshifting tumor.
    Sutherland KD; Ireland AS; Oliver TG
    Genes Dev; 2022 Mar; 36(5-6):241-258. PubMed ID: 35318269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.
    Tlemsani C; Pongor L; Elloumi F; Girard L; Huffman KE; Roper N; Varma S; Luna A; Rajapakse VN; Sebastian R; Kohn KW; Krushkal J; Aladjem MI; Teicher BA; Meltzer PS; Reinhold WC; Minna JD; Thomas A; Pommier Y
    Cell Rep; 2020 Oct; 33(3):108296. PubMed ID: 33086069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard therapy-resistant small cell lung cancer showing dynamic transition of neuroendocrine fate during the cancer trajectory: A case report.
    Ito F; Sato T; Emoto K; Kaizuka N; Yagi K; Watanabe R; Hashiguchi MH; Ninomiya H; Ikematsu Y; Tanaka K; Domoto H; Shiomi T
    Mol Clin Oncol; 2021 Dec; 15(6):261. PubMed ID: 34790350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance.
    Hwang S; Hong TH; Kim HK; Choi YS; Zo JI; Shim YM; Han J; Chan Ahn Y; Pyo H; Noh JM; Lee HY; Kim HJ; Park S; Ahn MJ; Park K; Lee SH; Choi YL; Kim J
    Mod Pathol; 2023 Jul; 36(7):100184. PubMed ID: 37054974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).
    Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY
    World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer.
    Patel AS; Yoo S; Kong R; Sato T; Sinha A; Karam S; Bao L; Fridrikh M; Emoto K; Nudelman G; Powell CA; Beasley MB; Zhu J; Watanabe H
    Sci Adv; 2021 Jan; 7(5):. PubMed ID: 33514539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular features and evolutionary trajectory of ASCL1
    Zhang X; Wang H; Liu W; Xiao Z; Ma Z; Zhang Z; Gong W; Chen J; Liu Z
    Br J Cancer; 2023 Mar; 128(5):748-759. PubMed ID: 36517551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer.
    Fushimi A; Morimoto Y; Ishikawa S; Yamashita N; Bhattacharya A; Daimon T; Rajabi H; Jin C; Hagiwara M; Yasumizu Y; Luan Z; Suo W; Wong KK; Withers H; Liu S; Long MD; Kufe D
    Mol Cancer Res; 2022 Sep; 20(9):1379-1390. PubMed ID: 35612556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.